한글목차

2024년 진행성 핵상마비(PSP) 진단을 받은 유병자 수는 263,657명이며, 2029년에는 268,041명으로 증가할 것으로 예측됩니다.

현재 PSP 시장에서 승인된 치료제는 없으며, PSP의 파이프라인에는 28개의 분자가 있으며, 등록 전 단계의 분자는 없으며, 1건은 3상 개발 중이고, 7건은 2상 개발 중입니다.

지난 10년간 PSP를 대상으로 52건의 임상시험이 진행되었습니다. 가장 많은 임상시험이 시작된 해는 2018년과 2024년으로 각각 8건, 2019년, 2021년, 2023년 각각 7건이었습니다.

지난 10년간 북미에서는 파트너십이 가장 일반적인 계약 형태였습니다. 아시아태평양에서는 라이선싱 계약이 주류를 이루었습니다. 유럽에서는 라이선싱 계약과 파트너십이 비슷한 비율로 계약 체결에 기여했습니다. 중남미와 아프리카에서는 라이선스 계약이 모든 거래를 차지했습니다.

세계의 진행성 핵상마비 시장에 대해 조사했으며, 질환 개요, 임상시험 동향, 파이프라인 개요, 향후 전망 등의 정보를 전해드립니다.

목차

제1장 목차

제1장 서문

제2장 주요 조사 결과

제3장 질병 상황

• 질환 개요
• 역학 개요
• 치료 개요

제4장 출시 약제 평가

• 주요 출시 약제
• 작용기전별 개요
• 분자 유형별 개요
• 제품 프로파일과 매출 예측

제5장 가격 설정과 상환 평가

• 연간 치료비
• 가격 설정과 상환까지 시간

제6장 파이프라인 약제 평가

• 중기에서 후기 단계 파이프라인 약제
• 개발 단계별 개요
• 작용기전별 개요
• 분자 유형별 개요
• 약제 고유의 상전이 성공률(PTSR)과 승인 가능성(LoA)
• 치료 분야와 적응증별 PTSR과 LoA

제7장 임상시험 평가

• 역사적 개요
• 상별 개요
• 상황별 개요
• 진행중 및 계획중인 시험의 상별 개요
• 가상 컴포넌트 시험
• 지역별 시험 개요
• 지역별 단일국 및 다국간 시험
• 상별 스폰서 상위 20개사
• 상황별 스폰서 상위 20개사
• 엔드포인트 상황별 개요
• 인종과 민족별 개요
• 등록 데이터
• 임상시험 실시 시설 상위 20개국
• 세계의 상위 20개 사이트
• 실현 가능성 분석 - 지역적 개요
• 실현 가능성 분석 - 벤치마크 모델

제8장 거래 상황

제9장 상업적 평가

제10장 향후 시장 성장 촉진요인

제11장 부록

영문목차

This reports provides a data-driven overview of the current and future competitive landscape in Progressive Supranuclear Palsy therapeutics.

GlobalData epidemiologists estimate that there will be 263,657 diagnosed prevalent cases of PSP in 2024, which is expected to increase to 268,041 diagnosed prevalent cases by 2029.

Currently, there are no approved treatments in the PSP market.

The PSP pipeline holds 28 molecules, with no assets in the pre-registration stage, one asset in Phase III development, and seven assets in Phase II development.

Over the past decade, 52 clinical trials have been conducted in PSP. The years with the most studies initiated were 2018 and 2024 with eight trials each, followed by 2019, 2021, and 2023 with seven trials each.

During the past decade, partnerships were the most common deal type in North America. Licensing agreements were dominant in the APAC region. In Europe, licensing agreements and partnerships contributed equally to completed deals. In South and Central America as well as in Africa, licensing agreements accounted for all transactions.

Scope

GlobalData's Progressive Supranuclear Palsy: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Progressive Supranuclear Palsy market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Progressive Supranuclear Palsy market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1 Table of Contents

1 Preface

• 1.1 Contents
• 1.2 Report Scope
• 1.3 List of Tables and Figures
• 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

• 3.1 Disease Overview
• 3.2 Epidemiology Overview
• 3.3 Treatment Overview

4 Marketed Drugs Assessment

• 4.1 Leading Marketed Drugs
• 4.2 Overview by Mechanism of Action
• 4.3 Overview by Molecule Type
• 4.4 Product Profiles and Sales Forecast

5 Pricing and Reimbursement Assessment

• 5.1 Annual Cost of Therapy
• 5.2 Time to Pricing and Reimbursement

6 Pipeline Drugs Assessment

• 6.1 Mid-to-late-stage Pipeline Drugs
• 6.2 Overview by Development Stage
• 6.3 Overview by Mechanism of Action
• 6.4 Overview by Molecule Type
• 6.5 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
• 6.6 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment

• 7.1 Historical Overview
• 7.2 Overview by Phase
• 7.3 Overview by Status
• 7.4 Overview by Phase for Ongoing and Planned Trials
• 7.5 Trials with Virtual Components
• 7.6 Overview of Trials by Geography
• 7.7 Single-Country and Multinational Trials by Region
• 7.8 Top 20 Sponsors with Breakdown by Phase
• 7.9 Top 20 Sponsors with Breakdown by Status
• 7.10 Overview by Endpoint Status
• 7.11 Overview by Race and Ethnicity
• 7.12 Enrollment Data
• 7.13 Top 20 countries for Trial Sites
• 7.14 Top 20 Sites Globally
• 7.15 Feasibility Analysis - Geographic Overview
• 7.16 Feasibility Analysis - Benchmark Models

8 Deals Landscape

• 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
• 8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

• 9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

• 11.1 Methodology
• 11.2 Methodology - Sales Forecast
• 11.3 Methodology - Pricing and Reimbursement
• 11.4 Methodology - PTSR and LoA Analysis
• 11.5 About the Authors
• 11.6 Contact Us
• 11.7 Disclaimer